More importantly, there were significantly decreased PD‐L1 levels in CD45+ and CD45+ CD11b+ cells, as well as tumor cells, indicating that our HSCs platform could effectively express PD‐1 for a long time, to block PD‐L1 (Figure 7I–K). The gene discussed is PTPRC; the disease is neoplasm.